Clinical Trial Update: BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating BIBW 2992 (afatinib) as add-on to gemcitabine/cisplatin in advanced biliary tract cancer; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Disease

Drugs mentioned

• BIBW 2992 (afatinib)
• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Johannes Gutenberg University Mainz | Conditions: Metastatic Disease | Phase 1 | Status: TERMINATED | Results posted: 2019-01-22